All questionsSpecific populations: Leqvio (inclisiran), all indications4 questions · 1 sourcePregnancy and breastfeedingCan Leqvio be used during pregnancy?“Discontinue LEQVIO when pregnancy is recognized. Alternatively, consider the ongoing therapeutic needs of the individual patient. Inclisiran increases LDL-C uptake and lowers LDL-C levels in the circulation, thus decreasing cholesterol and possibly other biologically active substances derived from cholesterol; therefore, LEQVIO may cause fetal harm when administered to pregnant patients based on the mechanism of action [see Clinical Pharmacology (12.1)]. In addition, treatment of hypercholesterolemia is not generally necessary during pregnancy. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of hypercholesterolemia for most patients.” (opens the source at this quote in a new tab)CopyFlag“There are no available data on the use of LEQVIO in pregnant patients to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.” (opens the source at this quote in a new tab)CopyFlag“There is a pregnancy safety study for LEQVIO. Report pregnancies by contacting Novartis at 1-888-669-6682 or usdrugsafety.operations@novartis.com.” (opens the source at this quote in a new tab)CopyFlagCan Leqvio be used while breastfeeding?“There is no information on the presence of inclisiran in human milk, the effects on the breastfed infant, or the effects on milk production. Inclisiran was present in the milk of lactating rats in all dose groups. When a drug is present in animal milk, it is likely that the drug will be present in human milk (see Data). Oligonucleotide-based products typically have poor oral bioavailability; therefore, it is considered unlikely that low levels of inclisiran present in milk will adversely impact an infant’s development during lactation. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for LEQVIO and any potential adverse effects on the breastfed infant from LEQVIO or from the underlying maternal condition.” (opens the source at this quote in a new tab)CopyFlagSpecific populationsIs a Leqvio dose change needed for kidney disease?“No dose adjustments are necessary for patients with mild, moderate, or severe renal impairment [see Clinical Pharmacology (12.3)]. LEQVIO has not been studied in patients with end stage renal disease [see Clinical Pharmacology (12.3)].” (opens the source at this quote in a new tab)CopyFlag“Despite the higher plasma exposures, reductions in LDL-C were similar across all groups based on renal function.” (opens the source at this quote in a new tab)CopyFlagIs a Leqvio dose change needed for liver disease?“No dose adjustment is necessary in patients with mild to moderate hepatic impairment. LEQVIO has not been studied in patients with severe hepatic impairment [see Clinical Pharmacology (12.3)].” (opens the source at this quote in a new tab)CopyFlag“In patients with moderate hepatic impairment, baseline PCSK9 levels were lower and reductions in LDL-C were less than those observed in patients with normal hepatic function.” (opens the source at this quote in a new tab)CopyFlag